The combination of dibenzazepine and a DOT1L inhibitor enables a stable maintenance of human naïve-state pluripotency in non-hypoxic conditions.
LIF
Naïve
Non-hypoxia
Pluripotent stem cell
Primed
Journal
Regenerative therapy
ISSN: 2352-3204
Titre abrégé: Regen Ther
Pays: Netherlands
ID NLM: 101709085
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
02
07
2020
revised:
04
08
2020
accepted:
12
08
2020
entrez:
11
1
2021
pubmed:
12
1
2021
medline:
12
1
2021
Statut:
epublish
Résumé
Conventional human pluripotent stem cells (hPSCs), known for being in a primed state, are pivotal for both basic research and clinical applications since such cells produce various types of differentiated cells. Recent reports on PSCs shed light on the pluripotent hierarchy of stem cells and have promoted the exploration of new stem cell states along with their culture systems. Human naïve PSCs are expected to provide further knowledge of early developmental mechanisms and improvements for differentiation programmes in the regenerative therapy of conventionally primed PSCs. However, practical challenges exist in using naïve-state PSCs such as determining the conditions for hypoxic culture condition and showing limited stable cellular proliferation. Here, we have developed new leukemia inhibitory factor dependent PSCs by applying our previous work, the combination of dibenzazepine and a DOT1L inhibitor to achieve the stable culture of naïve-state PSCs. The potential of these cells to differentiate into all three germ layers was shown both
Identifiants
pubmed: 33426214
doi: 10.1016/j.reth.2020.08.001
pii: S2352-3204(20)30066-3
pmc: PMC7770342
doi:
Types de publication
Journal Article
Langues
eng
Pagination
161-168Informations de copyright
© 2020 The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V.
Déclaration de conflit d'intérêts
The authors declare no potential conflicts of interest.
Références
Nat Commun. 2019 Feb 7;10(1):632
pubmed: 30733432
Stem Cell Reports. 2019 Oct 8;13(4):612-626
pubmed: 31522974
Sci Rep. 2019 Aug 15;9(1):11910
pubmed: 31417139
Mech Dev. 1996 Jul;57(2):123-31
pubmed: 8843390
Cell Stem Cell. 2016 Mar 3;18(3):323-329
pubmed: 26853856
Cell. 2014 Sep 11;158(6):1254-1269
pubmed: 25215486
Nat Chem Biol. 2014 Aug;10(8):632-639
pubmed: 24952596
Development. 2009 Apr;136(7):1063-9
pubmed: 19224983
Regen Ther. 2016 Jul 25;5:31-39
pubmed: 31245498
Nature. 2010 Sep 16;467(7313):285-90
pubmed: 20644535
Cell Stem Cell. 2009 Jun 5;4(6):487-92
pubmed: 19497275
Sci Rep. 2014 Jun 24;4:5228
pubmed: 24957798
Cell Stem Cell. 2009 Sep 4;5(3):237-41
pubmed: 19716359
PLoS Genet. 2011 May;7(5):e1002085
pubmed: 21637780
Cell Stem Cell. 2017 Jan 5;20(1):87-101
pubmed: 27989770
Cell Stem Cell. 2016 Oct 6;19(4):502-515
pubmed: 27424783
Cell Stem Cell. 2014 Oct 2;15(4):471-487
pubmed: 25090446
Cell Stem Cell. 2010 Nov 5;7(5):618-30
pubmed: 20888316
Curr Stem Cell Rep. 2018 Jun;4(2):149-157
pubmed: 31275803
Nat Biotechnol. 2008 Mar;26(3):313-5
pubmed: 18278034
Genome Biol. 2018 Apr 5;19(1):47
pubmed: 29622030
Proc Natl Acad Sci U S A. 2010 May 18;107(20):9222-7
pubmed: 20442331
Cell Stem Cell. 2018 Jun 01;22(6):851-864.e5
pubmed: 29804889
Curr Biol. 2014 Feb 3;24(3):340-6
pubmed: 24462001
Sci Rep. 2018 Apr 12;8(1):5884
pubmed: 29650979